N-3 FATTY ACIDS AND RESTENOSIS POST CORONARY ANGIOPLASTY

本研究的目的是描述一种 膳食补充n-3脂肪酸对功能和 冠心病患者的生化指标 接受选择性经皮腔内血管成形术 （PTCA）。 我们将使用该临床模型来研究N- 3多不饱和脂肪酸（PUFAs）的风险指标 动脉粥样硬化：血脂，血小板活化，血栓素 和前列环素形成以及血浆纤溶活性。 我们 还将研究长链n-3多不饱和脂肪酸的相互作用， 3-系列类二十烷酸的前体，与阿司匹林， 环氧合酶，用于预防PTCA后再狭窄。 我们将对n-3 PUFA的影响进行详细分析 与磷脂酶有关的血小板活化的初始步骤 C和A2。 我们将把在心肌细胞中观察到的变化 灌流对n-3 PUFA对类花生酸形成、血清 血脂，纤溶活性，膜磷脂 组成和相关酶系统。 我们在这个临床模型中的发现应该与增加 了解n-3 PUFAs在预防 动脉粥样硬化性疾病 尽管流行病学研究表明 作为一种关联，这项前瞻性临床研究旨在 证明n-3 PUFA摄入量 和减少血栓动脉粥样硬化性血管疾病，如果这样的话， 关系存在。 生物化学变化被认为 将监测与PUFA预防措施相关的情况。 由于再狭窄率相对较高（25- 35%） 在PTCA术后一年内，本研究是可行的。

The object of this study is to describe the long term effects of a dietary supplementation of n-3 fatty acids on functional and biochemical parameters in patients with coronary heart disease undergoing elective percutaneous transluminal angioplasty (PTCA). We will use this clinical model to study the effects of n- 3 polyunsaturated fatty acids (PUFAs) on risk indicators of atherosclerosis: serum lipids, platelet activation, thromboxane and prostacyclin formation, and plasma fibrinolytic activity. We will also study the interaction of long chain n-3 PUFAs, precursors of 3-series eicosanoids, with aspirin, an inhibitor of cyclooxygenase, which is used to prevent restenosis after PTCA. We will conduct a detailed analysis of the effects of n-3 PUFAs on initial steps of platelet activation related to the phospholipases C and A2. We will relate the changes observed in myocardial perfusion to effects of n-3 PUFAs on eicosanoid formation, serum lipids, plasma fibrinolytic activity, membrane phospholipid composition, and related enzyme systems. Our findings in this clinical model should be relevant to increasing the understanding of the effects of n-3 PUFAs in preventing atherosclerotic disorders. Though epidemiologic studies indicate an association, this prospective clinical study is designed to demonstrate a causal relationship between n-3 PUFA ingestion and decreased thromboatheromatous vascular disease, if such relationship exists. The biochemical changes thought to be associated with a preventive action of PUFAs will be monitored. Because of a relatively high rate of restenosis (25-35 percent) within one year post PTCA, this study is feasible.